Can A Multidisciplinary Initiative to Increase Adverse Drug Reaction Reporting Work?

Connecticut Medicine

Volumn 68, Issue 5, 2004, Pages 281-284

  Perkerson, Kristen A ^a,b   Quercia, Robert A ^a,b   Goldman, Monica ^b   Goddu, Ginger ^b   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; FLUMAZENIL; NALOXONE; PHYTOMENADIONE; PROTAMINE;

ARTICLE; CLINICAL PROTOCOL; COMPUTER PROGRAM; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MONITORING; HEALTH PROGRAM; INFORMATION PROCESSING; MANDATORY REPORTING; MEDICAL DOCUMENTATION; NURSE; PHARMACIST; RESPONSIBILITY; STATISTICAL ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDOTES; CONNECTICUT; DRUG THERAPY; EDUCATION, NURSING, CONTINUING; EDUCATION, PHARMACY, CONTINUING; HOSPITALS, UNIVERSITY; HUMANS; INFORMATION DISSEMINATION; JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS; MOTIVATION; PATIENT CARE TEAM; PROGRAM DEVELOPMENT; RISK MANAGEMENT; UNITED STATES;

EID: 2342471924     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. World Health Organization. International drug monitoring: The role of the hospital. Geneva, Switzerland: World Health Organization; 1966. Technical Report Series No. 425.
2. Beard K: Adverse reactions as a cause of hospital admission in the aged. Drugs Aging 1992; 2:356-67.
3. Koch KE: Adverse reactions. In: Brown T, ed. Handbook of institutional pharmacy practice, 3rd ed. Bethesda, American Society of Hospital Pharmacists, 1992; 279-91.
4. Prince BS, Goetz CM, Rihn TL, Olsky M: Drug-related emergency department visits and hospital admissions. Am J Hosp Pharm 1992; 49:1696-700.
5. DeSwarte RD. Drug allergy: Problems and strategies. J Allergy Clin Immunol 1984; 74:209-24.
6. American Society of Hospital Pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Hosp Pharm 1989; 46:336-7.
7. Schneider JK, Mion LC, Frengley JD: Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49:90-6.
8. Honig PK, Cantilena LR: Polypharmacy: Pharmacokinetic perspectives. Clin Pharmacokinet 1994; 26:85-90.
9. Stafford CT: Adverse drug reactions. Med Times 1988; 116:31-42.
10. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279:1200-5.
11. Saltiel E, Johnson E, Shane R: A team approach to adverse drug reaction surveillance: Success at a tertiary care hospital. Hosp Formul 1995; 39:226-8,231-2.
12. American Society of Health-System Pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Health-Syst Pharm 1995; 52:417-9.
13. Important Drug Warning for Mellaril® [thioridazine HCl]. Novartis Pharmaceuticals Co., East Hanover, New Jersey, July 7, 2000. Accessed at: www.fda.gov/medwatch/safety/2000/mellar.htm (12/1/2003).
14. Tikosyn® [dofetilide] product information, December 1999, Pfizer Labs, New York, NY.
15. Market withdrawal of Baycol® (cerivastatin). Bayer Co., West Haven, CT, August 8, 2001. Accessed at: www.fda.gov/medwatch/SAFETY/2001/Baycol2.htm (12/1/2003)
16. Tyler LS, Nickman NA: Hospital pharmacy compliance with JCAHO standards and ASHP guidelines for reporting adverse drug reactions. Am J Hosp Pharm 1992; 49:845-50.
17. Classen DC, Pestotnik SL, Evans RS, et al: Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266:2847-51.
18. Bero LA, Lipton HL, Bird JA: Characterization of geriatric drug related hospital readmissions. Med Care 1991; 29:989-1003.
19. Belton KJ: Attitude survey of adverse drug reaction reporting by healthcare professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol 1997; 52:423-7.
20. Leappe LL: Error in medicine. JAMA 1994; 272:1851-7.
21. Green CF, Mottram DR, Rowe PH, et al: Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol 2001; 51:81-6.
22. Jha AK, Kuperman GJ, Teich JM, et al: Identifying adverse drug events: Development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5:305-14.
23. Winterstein AG, Hatton RC, Gonzalez-Rothi R, et al: Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am J Health-Syst Pharm 2002; 59:1742-9.
24. Troutman WG, Doherty KM: Comparison of voluntary adverse drug reaction reports and corresponding medical records. Am J Health-Syst Pharm 2003; 60:572-5.
25. Voluntary reporting by healthcare professionals. Food and drug Administration Medwatch Program. Accesssed at: www.fda.gov/medwatch/report/hcp.htm (12/1/2003).